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Ossified blood vessels in primary familial brain
calcification elicit a neurotoxic astrocyte
response
Yvette Zarb,1,2 Ulrike Weber-Stadlbauer,3 Daniel Kirschenbaum,4 Diana Rita Kindler,5
Juliet Richetto,3 Daniel Keller,6 Rosa Rademakers,7 Dennis W. Dickson,7 Andreas Pasch,8
Tatiana Byzova,9 Khayrun Nahar,10 Fabian F. Voigt,2,11 Fritjof Helmchen,2,11 Andreas Boss,6
Adriano Aguzzi,4 Jan Klohs5 and Annika Keller1,2
Brain calciﬁcations are commonly detected in aged individuals and accompany numerous brain diseases, but their functional
importance is not understood. In cases of primary familial brain calciﬁcation, an autosomally inherited neuropsychiatric disorder,
the presence of bilateral brain calciﬁcations in the absence of secondary causes of brain calciﬁcation is a diagnostic criterion. To
date, mutations in ﬁve genes including solute carrier 20 member 2 (SLC20A2), xenotropic and polytropic retrovirus receptor 1
(XPR1), myogenesis regulating glycosidase (MYORG), platelet-derived growth factor B (PDGFB) and platelet-derived growth
factor receptor b (PDGFRB), are considered causal. Previously, we have reported that mutations in PDGFB in humans are
associated with primary familial brain calciﬁcation, and mice hypomorphic for PDGFB (Pdgfbret/ret) present with brain vessel
calciﬁcations in the deep regions of the brain that increase with age, mimicking the pathology observed in human mutation
carriers. In this study, we characterize the cellular environment surrounding calciﬁcations in Pdgfbret/ret animals and show that
cells around vessel-associated calciﬁcations express markers for osteoblasts, osteoclasts and osteocytes, and that bone matrix
proteins are present in vessel-associated calciﬁcations. Additionally, we also demonstrate the osteogenic environment around
brain calciﬁcations in genetically conﬁrmed primary familial brain calciﬁcation cases. We show that calciﬁcations cause oxidative
stress in astrocytes and evoke expression of neurotoxic astrocyte markers. Similar to previously reported human primary familial
brain calciﬁcation cases, we describe high interindividual variation in calciﬁcation load in Pdgfbret/ret animals, as assessed by ex
vivo and in vivo quantiﬁcation of calciﬁcations. We also report that serum of Pdgfbret/ret animals does not differ in calciﬁcation
propensity from control animals and that vessel calciﬁcation occurs only in the brains of Pdgfbret/ret animals. Notably, ossiﬁcation
of vessels and astrocytic neurotoxic response is associated with speciﬁc behavioural and cognitive alterations, some of which are
associated with primary familial brain calciﬁcation in a subset of patients.
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Introduction
Brain calciﬁcation is the most common incidental
ﬁnding seen in up to 20% of patients undergoing
neuroimaging (Deng et al., 2015). It is estimated that
30% of aged individuals present with brain calciﬁcations
(Nicolas et al., 2013a). Intracranial vessel-associated
calciﬁcations have been reported to accompany neurode-
generative diseases (e.g. Alzheimer’s, Parkinson’s, Nasu-
Hakola), type I interferonopathies, brain tumours and
other disorders (Mann, 1988; Vermersch et al., 1992;
Volpi et al., 2016). Functional contribution of
cerebrovascular calciﬁcation to clinical manifestation of
neurological diseases is debated (Puvanendran et al.,
1982; Forstl et al., 1992); however, the occurrence of vas-
cular calciﬁcations in peripheral diseases (e.g. chronic
kidney disease) can be detrimental (Zhu et al., 2012).
Moreover, although cerebrovascular calciﬁcations are
common, little is known about the mechanisms leading
to their formation. Thus, there is a void in knowledge
on the formation and functional consequences of cerebro-
vascular calciﬁcations.
In the case of primary familial brain calciﬁcation (PFBC)
the presence of calciﬁcations in the brain is a diagnostic
criterion. PFBC is a neuropsychiatric disease, in which all
patients present with bilateral, vessel-associated calciﬁca-
tions in the basal ganglia (Norman and Urich, 1960;
Gomez et al., 1989) in the absence of other secondary
causes of brain calciﬁcation (e.g. imbalance in serum cal-
cium and phosphate levels) (Manyam, 2005). Dominantly-
inherited PFBC is associated with mutations in four genes:
solute carrier 20 member 2 (SLC20A2) (Wang et al.,
2012), xenotropic and polytropic retrovirus receptor 1
(XPR1) (Legati et al., 2015), platelet-derived growth
factor B (PDGFB) (Keller et al., 2013), and platelet-
derived growth factor receptor b (PDGFRB) (Nicolas
et al., 2013b). Recessively inherited PFBC is associated
with mutations in myogenesis regulating glycosidase
(MYORG) (Yao et al., 2018). The estimated minimal
prevalence is 4.5 per 10 000, suggesting that PFBC is
not a rare disorder and is underdiagnosed (Nicolas
et al., 2018). The clinical penetration of PFBC is incom-
plete and heterogeneous comprising of psychiatric signs
(e.g. anxiety, psychosis), cognitive impairment, migraine,
and various movement disorders (e.g. ataxia, dystonia,
parkinsonism) (Manyam, 2005; Nicolas et al., 2013b;
Kasuga et al., 2014). Histologically, the most striking fea-
ture of PFBC is the encrusted capillaries (Miklossy et al.,
2005), where calciﬁcations cover vessels like ‘pearls on a
string’. The few available autopsy and case reports of pa-
tients with PFBC point to brain vascular insufﬁciency and
blood–brain barrier damage (Gomez et al., 1989;
Miklossy et al., 2005; Wszolek et al., 2006; Wider
et al., 2009; Baker et al., 2014; Kimura et al., 2016).
Although extensively calciﬁed brain areas show neuronal
preservation, neuronal pathology (e.g. Lewy bodies,
neuroﬁbrillary tangles or intracellular calciﬁcations) has
been described in PFBC cases (Miklossy et al., 2005;
Kimura et al., 2016). PET studies on genetically conﬁrmed
familial and idiopathic cases of basal ganglia calciﬁcation
have revealed presynaptic dopaminergic deﬁcits in patients
presenting with parkinsonism (Paschali et al., 2009;
Koyama et al., 2017). Changes in glucose metabolism in
non-calciﬁed striatal and cortical areas have been
described (Benke et al., 2004; Le Ber et al., 2007), indicat-
ing that calciﬁcations could interfere with neuronal
circuitry.
It is not known how mutations in SLC20A2 and XPR1,
which are a transmembrane inorganic phosphate (Pi) im-
porter and exporter, respectively, MYORG, a putative gly-
cosidase, and PDGFB and PDGFRB, a growth factor and
receptor, respectively, lead to a common pathology. Several
cell types at the neurovascular unit and in the brain paren-
chyma express these genes, and the contribution of each of
these cell types for disease development is not known. Most
of the described mutations in PFBC cases cause a loss-of-
function of the protein (Wang et al., 2012; Sanchez-
Contreras et al., 2014; Arts et al., 2015; Legati et al.,
2015; Vanlandewijck et al., 2015); however, some muta-
tions may exert a dominant negative effect (Larsen et al.,
2017), or cause a cellular mislocalization of the protein
(Taglia et al., 2017). Accordingly, the molecular and cellu-
lar mechanisms leading to capillary calciﬁcation in PFBC
may be multifactorial.
Ectopic soft tissue calciﬁcation is a common pathological
feature of many diseases (Rashdan et al., 2016; Nitschke
and Rutsch, 2017) and although the primary cause is dif-
ferent, the subsequent formation of bone cells has been
described in several calciﬁcation diseases. For example: in
atherosclerosis, end-stage renal disease, and monogenetic
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diseases such as generalized calciﬁcation of infancy,
Hutchinson-Gilford progeria, the mineralization is thought
to be driven by an active process resembling osteogenesis
(Johnson et al., 2006; Aikawa et al., 2007; Toussaint et al.,
2009; Villa-Bellosta et al., 2013; Leopold, 2015; Benz
et al., 2017). It is not known if vessel calciﬁcation in
PFBC shares similarities with physiological bone formation.
Hence, we addressed this question with a PFBC [Pdgfb
hypomorph, Pdgfbret/ret (Keller et al., 2013)] mouse model
and genetically conﬁrmed PFBC cases. We report that the
cells surrounding calciﬁed nodules express markers for
osteoblasts, osteoclasts and osteocytes. In addition, we
found that bone matrix proteins are deposited in calciﬁca-
tions and showed that this osteogenic environment accom-
panies a neurotoxic astrocyte response in Pdgfbret/ret mice.
Of note, Pdgfbret/ret animals present speciﬁc behavioural
and cognitive alterations, similar to those described in a
subset of patients with PFBC.
Materials and methods
Mice
In this study, Pdgfbret/ret (Pdgfb hypomorphs) and Pdgfbret/wt
(controls) mice of both genders were used (Lindblom et al.,
2003; Keller et al., 2013). The mice were 2–4 months or 8–12
months of age. Experiments on mice were carried out in ac-
cordance to the protocols approved by the Cantonal
Veterinary Ofﬁce Zurich (permit numbers ZH196/2014,
ZH067/2015, and ZH151/2017). The mice were housed
under a 12-h light/dark cycle and were given food and water
ad libitum.
Primary familial brain calcification
patients
Genetically conﬁrmed PFBC autopsy cases [SLC20A2 genomic
deletion (p.Met1_Val652del), SLC20A2 p.Ser113*, PDGFRB
p.(Arg695Cys)] were from Mayo Clinic Florida Brain Bank
and have been described previously (Baker et al., 2014;
Sanchez-Contreras et al., 2014). The study protocol on aut-
opsy samples was approved by the Swiss Ethics Committee
(Zu¨rich, KEK-2018–00877).
Antibodies, peptides and
bisphosphonates
Primary antibodies used for immunoﬂuorescence staining are
listed in Supplementary Table 1.
All ﬂuorescently-labelled (Alexa 488, Cy3, DyLight 649) sec-
ondary antibodies made in donkey (anti-rabbit, anti-rat and
anti-goat) suitable for multiple labelling were purchased from
Jackson Immunoresearch.
Peptide DSS6 conjugated to 5(6)FAM [5(6)-carboxyﬂuores-
cein] was purchased from JPT Peptide Technologies.
Bisphosphonates AF647-RISPC, 5(6)FAM-zolendronate
and AF647-risedronate were purchased from Biovinc. The
250-mm thick cleared brain slices were incubated overnight
with the peptide DSS6 or bisphosphonates, followed by a
washing step with phosphate-buffered saline (PBS) and mount-
ing in ProLong Gold Antifade (Invitrogen).
Immunohistochemistry on mouse
brain vibratome slices
Mice were deeply anaesthetized and transcardially perfused
with ice-cold PBS followed by 4% paraformaldehyde (PFA),
pH 7.2. Brains were removed and post-ﬁxed 4–5 h in 4% PFA
at 4C. Mouse brains were sectioned with a vibratome (Leica
VT1000S) into 60-mm thick slices. Vibratome slices were
blocked with 1% bovine serum albumin (BSA), 0.1%
TritonTM X-100 in PBS and incubated overnight at 4C, fol-
lowed by an incubation of 2 days with primary antibodies at
4C. Slices were washed with 0.5% BSA, 0.05% TritonTM X-
100 in PBS and incubated overnight with secondary
antibodies. Slices were stained with DAPI, followed by a
ﬁnal washing step in PBS, and mounted in ProLong Gold
Antifade (Invitrogen). Immunohistochemistry stains were
imaged using a confocal microscope [Leica SP5, 20NA (nu-
merical aperture): 0.7, 63 NA: 1.4] or a stereomicroscope
(Zeiss Axio Zoom.V16, 1NA: 0.25). Images were analysed
using the image-processing software Imaris (Bitplane). For
stains that exhibited a salt-and-pepper noise, a median ﬁlter
of 5 5 5 was applied to remove the noise. For all immu-
nohistochemical studies, a minimum number of three animals
was investigated per staining.
Quantification of calcifications and
vessel density on brain serial sections
Brains were serially sectioned into 50-mm thick slices using a
vibratome (Leica VT1000S). Fifty-ﬁve sequential coronal sec-
tions were taken for immunohistochemistry, where the ﬁrst
section contained the posterior part of the commissura ante-
riori and the last section contained the posterior part of the
hypothalamus and zona incerta. All vibratome sections were
stained with antibodies against osteocalcin and collagen IV
(Supplementary Table 1). Immunohistochemistry stains for
the quantiﬁcation of calciﬁcations and vessel density were
imaged using a confocal microscope (Leica SP5, 10NA:
0.4). Images were acquired from the thalamic regions, consist-
ing of two horizontal tiles from the left and right hemispheres.
For quantiﬁcation of calciﬁcations, images were analysed using
the image-processing software Imaris (Bitplane), where a sur-
face for the osteocalcin staining (calciﬁcation channel) was
created. Vessel density was quantiﬁed on 22 brain sections
divided into right and left hemispheres from areas showing a
high interindividual variation in calciﬁcation load. Vessels
were identiﬁed using anti-collagen IV immunostaining and
the vessel density was quantiﬁed in Fiji (Schindelin et al.,
2012) using vessel analysis plugin (version 1.1) with minor
modiﬁcations. Prism7 software (GraphPad) was used to per-
form statistical analysis (one-way ANOVA, Pearson correl-
ation test).
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Immunohistochemistry on human
brain sections
Parafﬁn-embedded brain sections were deparafﬁnized and
hydrated. Antigen retrieval was performed using 0.01M citrate
buffer, pH 6.0 at 95C. Tissue sections were blocked with 5%
donkey serum, 0.2% TritonTM X-100 in PBS for 1 h at room
temperature, followed by an overnight incubation with pri-
mary antibodies at 4C. Tissue sections were washed with
PBS and incubated for 2 h at room temperature with secondary
antibodies. Nuclei were visualized using DAPI, followed by an
incubation with ﬁltered 0.3% Sudan black in 70% ethanol for
10min. Slices were washed and mounted in ProLong Gold
Antifade (Invitrogen). Immunohistochemistry stains were
imaged using a confocal microscope (Leica SP5, 20NA:
0.7, 63NA: 1.4). Images were analysed using the image-pro-
cessing software Imaris (Bitplane).
Whole brain clearing, labelling of
brain calcifications and SPIM imaging
of calcifications
Mouse brain tissue for whole brain clearing was prepared ac-
cording to a published protocol (Chung et al., 2013), with
minor modiﬁcations. Cleared brains were stained for 3 days
at room temperature using 0.5 nmol of AF647-risedronate
(Biovinc). The stained brains were washed in PBS and placed
in refractive index matching solution [RIMS; 85% (w/v)
Histodenz (Sigma)] for imaging. Brains were attached to a
small weight and loaded into a quartz cuvette, then submerged
in RIMS and imaged using a home-built mesoscale single-plane
illumination microscope (SPIM), with a 1.25 zoom (ﬁeld of
view 10.79mm; pixel size: 5.27 mm). Four ﬁelds of view were
used to cover the whole mouse brain and were stitched in Fiji.
The technical details of in house-built SPIM are described else-
where (www.mesospim.org).
MRI
All MRI was performed on a 7T small animal MR
Pharmascan (Bruker Biospin) equipped with an actively
shielded gradient set of 760mT/m with an 80 ms rise time
and operated by a Paravision 6.0 software platform. Phase
mapping and susceptibility-weighted imaging (SWI) was per-
formed as described previously, with minor modiﬁcations
(Klohs et al., 2011). In brief, a circular polarized volume res-
onator was used for signal transmission and an actively
decoupled mouse brain quadrature surface coil with integrated
combiner and preampliﬁer was used for signal receiving
(Bruker BioSpin). Mice were anaesthetized with an initial
dose of 4% isoﬂurane (Abbott) in oxygen/air (200:800ml/
min) mixture and were maintained spontaneously breathing
1.5% isoﬂurane, supplied via a nose cone. Mice were placed
on a water-heated support to keep body temperature within
36.5  0.5C, monitored with a rectal temperature probe. T2*-
weighted gradient-images were acquired with a ﬂow-compen-
sated Fast Low-Angle Shot (FLASH) gradient-echo sequence.
Sequence parameters were echo time = 15ms, repetition
time = 350ms, ﬂip angle = 30, and number of averages = 16.
Eleven horizontal slices of 0.5mm thickness were recorded
with a ﬁeld of view = 20mm 20mm, an image ma-
trix = 331 331 to give a spatial resolution = 60 mm 60 mm.
Fieldmap-based shimming was performed prior data acquisi-
tion using the automated MAPshim routine to improve the
homogeneity of the magnetic ﬁeld.
Image post-processing
Phase maps and susceptibility-weighted images were generated
using Paravision software (Bruker). Data were processed in a
standard fashion with a 2D Fourier transform to compute the
magnitude images. A phase unwrapping Gaussian ﬁlter was
used to remove slowly varying phase shifts. Phase masks
were created by setting all positive phases to 1 and by scaling
negative phases linearly between 0 and 1. These masks were
multiplied four times with the corresponding magnitude image
to create susceptibility-weighted images.
Quantification of calcifications on
images generated using
susceptibility-weighted imaging
Eleven SWI datasets were analysed. Serial images 4–10 con-
taining calciﬁcation prone regions were selected for quantiﬁca-
tion. SWI images were compared with their phase image
counterparts to ensure that the signal was due to a diamag-
netic signal (i.e. presence of calciﬁcations). SWI images were
processed using Fiji (ImageJ) (Schindelin et al., 2012), where
images were contrast enhanced, thresholded and converted to
a binary image. The area covered by calciﬁcations in a region
of interest in one SWI image was calculated from the obtained
binary images. The region of interest used on serial SWI slices
remained constant across the cohort analysed. Prism7 software
(GraphPad) was used for statistical analysis (one-way
ANOVA).
Behavioural studies
Adult mice (12 to 16 weeks) underwent behavioural testing.
Testing began after 2 weeks of acclimatization in new holding
room. Behavioural testing was carried out during the light
phase in a dimly lit room. For all the tests except the light-
dark box test and prepulse inhibition, a digital camera was
mounted above the maze. Images were captured at a rate of
5Hz and transmitted to a PC running the EthoVision tracking
system (Noldus Information Technology, The Netherlands).
For all behavioural experiments except for the light-dark
box, two cohorts of mice were tested on separate occasions,
where cohort I consisted of 18 mice (eight Pdgfbret/ret; 10 con-
trols) and cohort II of 20 mice (10 Pdgfbret/ret; 10 controls).
The number of animals used for each test is given in the re-
spective ﬁgure legends.
Light-dark box
The light-dark box consisted of four identical two-way shuttle
boxes (30 3024 cm; Multi Conditioning System, TSE
Systems). Boxes were separated by a dark Plexiglas wall,
and interconnected by an opening (3.5 10 cm) in the parti-
tion wall, thus allowing the animal to freely traverse from one
compartment to another. This wall divided the compartment
into a dark (1 lx) and a brightly illuminated (100 lx) compart-
ment. Each mouse was placed in the centre of the dark
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compartment and was allowed to move freely for 10min.
Innate anxiety (IA) was indexed as a per cent of time spent
in the light compartment during 10min of exploration:
IA ¼ time spent in light compartment
total time
 
 100
 
ð1Þ
Total distance moved was measured to ascertain that the per
cent of time spent in the light compartment was not con-
founded by changes in locomotor activity.
Open field
The locomotor activity of mice was assessed in an open ﬁeld
set up, as described in detail elsewhere (Meyer et al., 2005).
The apparatus consisted of white Plexiglas and was located
in a testing room under diffuse lighting. A digital camera was
mounted directly above the four arenas. Images were captured
at a rate of 5Hz and transmitted to a PC running the
Ethovision (Noldus Information Technology, The
Netherlands) tracking system. The mice were gently placed in
a corner of the arena, and allowed to freely explore for 45min,
where the dependent measure (total distance moved) is ex-
pressed as a function of 5-min bins.
Prepulse inhibition
The set-up and analysis used was the same as described in
(Weber-Stadlbauer et al., 2017). For each of the three pulse
intensities (100, 110, or 120 dBA) prepulse inhibition (PPI)
was indexed as the percent of inhibition of the startle response
detected in pulse-alone trials:
PPI ¼ 100 1 mean reactivity on prepulse and pulse trials
mean reactivity on pulse alone trials
  
ð2Þ
PPI was calculated for each animal, and for three prepulse
intensities ( +6, +12, or +18 dBA above background). One
female Pdgfbret/ret mouse was excluded from the analysis as
the calculated percentage of mean PPI was negative, indicating
a lack of responsiveness from the individual mouse.
Social interaction
We assessed social interaction using a social approach test in a
modiﬁed Y-maze as established before (Richetto et al., 2017;
Weber-Stadlbauer et al., 2017). The per cent of time spent (TS)
with the live mouse was calculated as follows:
TS ¼ 100 time spent with the live mouse
time spent with the live mouseþ time spent with the dummy object
 
ð3Þ
This value was used to assess relative exploration time be-
tween a congenic mouse and an inanimate dummy object.
Total distance moved was measured to ascertain that the per-
cent of time spent with the mouse was not confounded by
changes in locomotor activity. One female Pdgfbret/ret mouse
was excluded from the analysis since it did not explore all
arms of the arena during the test.
Spontaneous alternation test
The apparatus was identical to the one described above for
assessing social interaction. The apparatus was located in an
experimental testing room under dim diffuse lighting. The ap-
paratus was made of transparent Plexiglas and consisted of
three identical arms (50 9 cm; lengthwidth) surrounded
by 10-cm high transparent Plexiglas walls. The three arms
radiated from a central triangle (8 cm on each side) and were
spaced 120 from each other. The percentage of spontaneous
alternation (SAT) was calculated as follows:
SAT ¼ 100 number of alternations
number of arm entries 2
 
ð4Þ
Statistical analyses
Results are expressed as mean  standard error of the mean
(SEM). Following statistical tests were performed on Prism7
software (GraphPad): statistical analysis between two groups
was assessed using a two-tailed t-test. Statistical analysis be-
tween multiple groups was assessed using one-way ANOVA
with Tukey correction for multiple comparison. To assess for
correlation between vessel density and calciﬁcation load, a
Pearson correlation test was performed.
Behavioural studies
Dependent measures obtained in the SAT, the social inter-
action and the light/dark box test were analysed using
2 2 2 (genotype gender cohort) ANOVA. All
dependent measures in the open ﬁeld test were analysed
using 2 2 2 (genotype gender cohort) ANOVA or
using 2 2 2 9 (genotype gender cohort bins) re-
peated measure-ANOVA. In the PPI test, the per cent of PPI
was analysed using a 2 2 3 3 (genotype gender pulse
level prepulse level) repeated measures ANOVA. The reactiv-
ity to pulse-alone trials was analysed using a 2 2 3 (geno-
type gender pulse level) repeated measures ANOVA, and
the reactivity to prepulse-alone trials using a 2 2 3 (geno-
type gender prepulse level) repeated measures ANOVA.
Statistical signiﬁcance was set at P5 0.05. All statistical ana-
lyses were performed using the statistical software StatView
(SAS institute Inc.; version 5.0.1).
Data availability
The raw data that support the ﬁndings of this study are avail-
able from the corresponding author upon reasonable request.
Results
Ectopic calcifications in Pdgfbret/ret
mice are confined to the brain
The clinical symptoms of PFBC are conﬁned to the nervous
system. However, microangiopathy in skin biopsies in
PDGFB, PDGFRB and XPR1 mutation carriers has been
reported (Biancheri et al., 2016; Nicolas et al., 2017).
Furthermore, Slc20a2 deﬁciency leads to skeletal abnorm-
alities (Dickinson et al., 2016). Therefore, we investigated
whether Pdgfbret/ret animals also exhibit abnormalities in
the skeleton and present with soft tissue calciﬁcations out-
side of the CNS using a micro-computed tomography
(mCT). Control and Pdgfbret/ret animals were scanned, and
3D rendered mCT images were constructed. We could not
detect any macroscopic differences in the skeleton of
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control versus Pdgfbret/ret animals (Supplementary Fig. 1A).
The extra-skeletal signal observed in the abdomen
(Supplementary Fig. 1A) both in Pdgfbret/ret and control
mice was conﬁned to the gut (Supplementary Fig. 1B),
thus this signal is likely due to the chow fed to the mice.
Next, we investigated for ectopic calciﬁcation in the soft
tissue, where we detected calciﬁcations in the brain of
Pdgfbret/ret animals, which is consistent with our previously
published data (Keller et al., 2013; Vanlandewijck et al.,
2015) (Supplementary Fig. 1C); however, we did not detect
calciﬁcations on large central and peripheral vessels, such
as the aorta (Supplementary Fig. 1D) and the femoral
artery (Supplementary Fig. 1E).
Although we did not detect soft tissue calciﬁcation out-
side the brain, we investigated nevertheless if Pdgfbret/ret
animals show systemic disturbances that could lead or con-
tribute to the vessel calciﬁcation in the brain. We applied a
recently developed functional test (T50 test) (Pasch et al.,
2012) to determine the calciﬁcation propensity of sera of
Pdgfbret/ret and control animals. This test estimates the ef-
ﬁciency of a serum’s anti-calciﬁcation system to inhibit the
formation of calcium phosphate nanocrystals and measures
the time point of the transformation (T50) of primary cal-
ciprotein particles (amorphous) to secondary calciprotein
particles (crystalline) by challenging the tested serum with
supersaturated calcium and phosphate solutions (Pasch
et al., 2012). No statistically signiﬁcant difference in
serum T50 values (i.e. calciﬁcation propensity) between
Pdgfbret/ret and control animals was detected
(Supplementary Fig. 1F). These data add additional evi-
dence that serum’s pro-and anti-calcifying factors are not
imbalanced in PFBC and systemic alterations do not con-
tribute to the pathogenesis of PFBC.
Interindividual variation in
calcification load in Pdgfbret/ret animals
The presence of bilateral brain calciﬁcations is the common
denominator in all PFBC mutation carriers; however, the
load of calciﬁcation shows a signiﬁcant interindividual vari-
ation (Nicolas et al., 2013b). To estimate the variation in
calciﬁcation load between Pdgfbret/ret animals, we quantiﬁed
calciﬁcations in vivo in the deep regions of the brain using
SWI and phase mapping. Both techniques use fully velocity
compensated gradient-echo sequence data. The post-process-
ing of the data reveals signal changes due to the presence of
compounds that disturb the magnetic ﬁeld, such as iron or
calcium. In addition, ﬁltered phase images allow the discrim-
ination between diamagnetic (calcium) and paramagnetic
(iron) compounds because they cause opposite phase shifts
(Haacke, 2006). We acquired gradient-echo datasets from
Pdgfbret/ret and control animals for SWI and phase post-pro-
cessing, and reconstructed phase maps to determine the type
of the compound causing magnetic ﬁeld disturbances.
Susceptibility-weighted images of Pdgfbret/ret animals
showed hypointensities in calciﬁcation-prone regions
(Fig. 1A, yellow arrows) and the phase map analysis
showed that these disturbances are due to calcium and not
iron. No changes in tissue contrast were detected in images
of control animals (Fig. 1A). Quantiﬁcation of calciﬁcation
load using susceptibility-weighted images revealed regional
difference in calciﬁcation load between individual
Pdgfbret/ret animals (Fig. 1B). In addition, the total calciﬁca-
tion load quantiﬁcation using susceptibility-weighted images,
showed also a statistically signiﬁcant difference between
tested animals (Fig. 1C). Thus, the SWI and phase-analysis
approach to determine the calciﬁcation load further con-
ﬁrmed the presence of calcium in vessel-associated lesions
and demonstrated a regional, up to 3-fold, interindividual
variation in the calciﬁcation load. These data show that des-
pite of genetic homogeneity and controlled environment, cal-
ciﬁcation load in brains of Pdgfbret/ret animals is variable
which is consistent with the calciﬁcation phenotype observed
in human patients with PFBC.
Brain calcifications in Pdgfbret/ret mice
bind bisphosphonates
Our current and previous analysis of vessel-associated cal-
ciﬁcations in Pdgfbret/ret mouse brains demonstrated the
presence of calcium and phosphate-containing lesions,
which stained with histological bone stains
[Supplementary Fig. 1A and C, see also Keller et al.
(2013)]. We therefore extended the characterization of the
bone-like consistency of vessel-associated calciﬁcations by
testing if these structures bind bisphosphonates.
Bisphosphonates are chemical derivatives of pyrophosphate
(PPi), which similarly to PPi, bind to calcium hydroxyapa-
tite crystals in the bone with high afﬁnity (Zhang et al.,
2007). We tested several ﬂuorescently labelled bisphospho-
nates [AF647-RIS, AF647-RISPC, 5(6)-FAM-ZOL], which
differ in their afﬁnity to hydroxyapatite (Sun et al., 2016).
We observed that all bisphosphonates labelled brain calci-
ﬁcations although with different intensities. AF647-risedro-
nate was selected to label calciﬁcations in cleared whole
brains of Pdgfbret/ret mice. Whole brain imaging further
conﬁrmed the localization of calciﬁcations in the deep
brain regions, occurring in a bilateral conﬁguration
(Fig. 1D and Supplementary Video 1), as described previ-
ously (Keller et al., 2013). These data indicate the presence
of hydroxyapatite, the crystalline form of calcium and
phosphate present in bone and lend further support to
the notion that vessel-associated nodules in Pdgfbret/ret
mice have a bone-like consistency.
Bone matrix proteins are present in
brain calcifications in Pdgfbret/ret mice
Having established that vessel-associated structures contain
hydroxyapatite, we aimed to further characterize the extra-
cellular matrix (ECM) composition of these and therefore
stained brain tissue with antibodies recognizing bone ECM
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Figure 1 Interindividual variation in calcification load and osteoid-like consistency of brain calcifications in Pdgfbret/ret animals.
(A) SWI sequence images and phase maps of the mouse brain. Calcifications (yellow arrows) were observed as black structures in the thalamic
region on susceptibility-weighted images and as diamagnetic phase shifts on the corresponding phase maps. (B) Quantification of the calcification
load in individual mice using susceptibility-weighted images, where calcification load is plotted against an individual imaged brain section (ventral to
dorsal) and presented as box-plots indicating the mean and whiskers indicating minimum and maximum values, n = 6. (C) Quantification of
calcification load using SWI analysis shows a significant difference between six individual Pdgfbret/ret mice (one-way ANOVA; P = 0.0284). Bar
indicates the mean. (D) Bisphosphonates (AF647-RIS, in yellow) stain brain calcifications in cleared whole brains of Pdgfbret/ret animals. [D(i)]
Sagittal view of a surface rendered image of the bisphosphonate staining. [D(ii)] Transverse view of bisphosphonate staining showing the bilateral
distribution of brain calcifications. White dotted line delineates brain tissue. Scale bars = 3000mm (D), 1000 mm [D(i)], 2000 mm [D(ii)]. (E) A
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components. Immunohistological analysis showed several
bone matrix proteins in these brain lesions, such as colla-
gen I (Fig. 1E), osteocalcin (Fig. 1E–G) and osteopontin
(Fig. 1F). Co-staining with a blood vessel marker conﬁrmed
that aggregates positive for bone proteins are associated
with vessels (Fig. 1G). Even though osteopontin and colla-
gen I are abundant in bone, these proteins are expressed by
many tissues other than bone. To the best of our know-
ledge, osteocalcin is secreted solely by osteoblasts (Gorski,
2011) and thus, the presence of osteocalcin indicates the
presence of true bone forming cells in the brains of
Pdgfbret/ret animals. Taken together, these results demon-
strate that brain vessel-associated calciﬁcations in
Pdgfbret/ret mice have an osteoid consistency, containing
collagen I, as well as non-collagenous bone proteins, such
as osteopontin and osteocalcin.
The ﬁnding that calciﬁcations can be labelled using anti-
bodies against bone proteins gave us the opportunity to ad-
dress whether the observed high variation in calciﬁcation
load (Fig. 1B and C) is due to differences in vessel density
among individual Pdgfbret/ret mice. Blood vessels and vessel-
associated calciﬁcations were visualized using immunohisto-
chemistry and imaged using the laser scanning confocal
microscope. We observed a high variance between individual
mice in the total number of calciﬁcations (Fig. 1H), where
the calciﬁcation load differed regionally up to 3-fold (Fig.
1I), similar to calciﬁcation quantiﬁcation data obtained
using susceptibility weighting and phase mapping. We deter-
mined the vascular density in brain regions that showed the
highest difference in calciﬁcation load. We did not observe a
correlation between vessel density and calciﬁcation number
(R2 = 0.001; Fig. 1J) and, thus, differences in calciﬁcation
number between different Pdgfbret/ret animals cannot be ex-
plained by differences in vessel density.
Osteoclast-like cells surround
vessel-associated calcifications in
Pdgfbret/ret mouse brains
The presence of osteocalcin in vessel-associated calciﬁca-
tions (Fig. 1E–G) prompted us to investigate if cells ex-
pressing bone cell markers (osteoclasts, osteoblasts and
osteocytes) can be detected. Osteoclasts are multinucleated
giant cells that express tartrate-resistant acid phosphatase
(TRAP), a widely used histochemical marker for osteoclasts
(Boyle et al., 2003). However, we were not able to observe
multinucleated cells nor cells positive for TRAP enzymatic
activity (not shown) around calciﬁcations. We next investi-
gated whether cathepsin K, a protease that is secreted by
osteoclasts (Boyle et al., 2003), can be detected around
calciﬁcations. We observed cathepsin K-positive cells
around calciﬁcations (Fig. 2A) and calciﬁcations positive
for this protease. The receptor activator of nuclear factor
B (RANK)/ RANK ligand (RANKL) signalling axis is im-
portant for bone remodelling, where osteoblasts express
RANKL, which interacts with the receptor (RANK) ex-
pressed on the surface of osteoclasts, promoting osteoclast
maturation (Boyle et al., 2003). We observed RANK-posi-
tive cells surrounding calciﬁed nodules (Fig. 2B).
Altogether, we detected the expression of a subset of osteo-
clast markers by cells surrounding vessel-associated
calciﬁcations.
Osteoblast-like cells surround
vessel-associated calcifications in
Pdgfbret/ret mouse brains
Osteoblasts in bone express the transcription factor
RUNX2, which is essential for skeletogenesis (Johnson
et al., 2006). In Pdgfbret/ret mouse brains, RUNX2-positive
cells were found in close proximity to vessel-associated cal-
ciﬁcations, where the localization of this transcription
factor was nuclear (Fig. 2D), indicative of activation and
transcriptional activity. We also detected RUNX2-positive
cells in control animals in locations similar to those in
Pdgfbret/ret mice. In contrast, RUNX2 was localized dif-
fusely in the cytoplasm in control animals (Fig. 2D,
yellow arrows). Another osteoblast marker, expressed by
committed progenitors, is tissue non-speciﬁc alkaline phos-
phatase (ALPL) (Johnson et al., 2006). ALPL staining re-
vealed a zonated endothelial expression in both control and
Pdgfbret/ret animals (Supplementary Fig. 2). In addition, we
detected single, ALPL-positive cells that were negative for
endothelial markers in calciﬁcation-prone regions in
Pdgfbret/ret mice (Supplementary Fig. 2C), indicating the
presence of osteoblast progenitors. To assess further if
vessel-associated calciﬁcations present an osteoblastic envir-
onment in Pdgfbret/ret animals, we stained brain sections
Figure 1 Continued
subset of osteocalcin-positive (in red) calcifications are positive for collagen I (in cyan). In addition, collagen I-positive cells are observed around
calcifications. Nuclei are visualized using DAPI (in white). Scale bar = 30 mm, magnified image = 4 mm. (F) A subset of osteocalcin-positive (in red)
calcifications are positive for osteopontin (in white). Scale bar = 10 mm. (G). Osteocalcin-positive (in red) calcifications are vessel-associated (in
green). Brain calcifications are surrounded by reactive astrocytes (in cyan). Scale bar = 20 mm. (H) Quantification of calcification number using
immunohistochemistry shows a significant difference between four individual Pdgfbret/ret mice (one-way ANOVA; P = 0.0001). Bar indicates the
mean. (I) Number of calcifications increase on the rostral-caudal axis. X-axis shows the number of analysed brain slices. Illustrative brain sections
indicate an approximate anatomical position of analysed brain sections (Image credit: Allen Institute). n = 4. (J) Vessel density is plotted against the
calcification load in the brain regions which show variable calcification load (sections 43–55, see I) (Pearson correlation, R2 = 0.0012). In total, 153
brain sections from four Pdgfbret/ret mice were analysed.
892 | BRAIN 2019: 142; 885–902 Y. Zarb et al.
D
ow
nloaded from
 https://academ
ic.oup.com
/brain/article-abstract/142/4/885/5364607 by U
niversity of Zurich user on 16 M
ay 2019
with a peptide DSS65(6)FAM, which has been reported to
bind speciﬁcally to osteoblastic sites in bone (Zhang et al.,
2012). Indeed, this peptide stained calciﬁcations in cleared
brains (Fig. 2C, yellow arrows) further conﬁrming the pres-
ence of an osteoblastic environment of brain calciﬁcations
in Pdgfbret/ret animals.
Osteocyte-like cells reside within
vessel-associated calcifications in
Pdgfbret/ret mouse brains
In bone, osteoblasts become embedded in osteoid tissue and
become osteocytes, stellate-shaped cells important for bone
maintenance (Bonewald, 2011). Osteocytes express secreted
glycoprotein sclerostin, a protein not expressed by other
bone cells (Bonewald, 2011). Immunohistological detection
of sclerostin revealed the presence of sclerostin immuno-
positivity in vessel-associated calciﬁcations in Pdgfbret/ret
animals (Fig. 2E). Furthermore, within sclerostin-positive
calciﬁcations, we detected entrapped cell nuclei (Fig. 2E,
yellow arrow) reminiscent of bone, where osteocytes
reside within the bone structure (Bonewald, 2011). In add-
ition, we stained for another osteocyte marker—the cell
surface protein podoplanin (Wetterwald et al., 1996)—but
could not detect podoplanin reactivity within calciﬁcations.
Surprisingly, podoplanin was expressed by reactive astro-
cytes surrounding calciﬁcations (Fig. 4A). Altogether, the
presence of bone proteins, osteoclast-, osteoblast- and
osteocyte-like cells at the site of vessel calciﬁcations in
brains of Pdgfbret/ret animals indicate the presence of an
osteogenic environment.
Genetically confirmed PFBC cases
exhibit an osteogenic environment
around brain calcifications
Having established the presence of an osteogenic environ-
ment around vessel-associated calciﬁcations in Pdgfbret/ret
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animals, we wanted to evaluate the validity of these ﬁnd-
ings to human PFBC. Thus, we investigated if brain calci-
ﬁcations in the animal model exhibit a similar
microenvironment as in genetically conﬁrmed PFBC pa-
tients carrying mutations in SLC20A2 (p.Met1_Val652del
and p.Ser113*) or in PDGFRB (p.Arg695Cys). Similar to
calciﬁcations in Pdgfbret/ret brains, calciﬁcations in PFBC
brains showed the presence of osteocalcin, collagen I and
osteopontin (Fig. 3A–C). We also observed the presence of
cathepsin K, a protein secreted by osteoclasts, deposited in
brain calciﬁcations (Fig. 3D). Furthermore, we detected the
nuclear localization of RUNX2, in cells in proximity to
brain calciﬁcations (Fig. 3E). These results demonstrate
for the ﬁrst time that brain vessel-associated calciﬁcations
in PFBC patients have an osteoid consistency and are sur-
rounded by an osteogenic environment. In addition, these
data further afﬁrm that the Pdgfbret/ret mouse model recap-
itulates pathological changes seen in PFBC cases.
Neurotoxic astrocytes surround
vessel-associated calcifications
Our observation that reactive astrocytes surrounding calci-
ﬁcations express podoplanin (Fig. 4A) prompted us to ex-
plore the nature of reactive astrocytes surrounding
calciﬁcations. Brain regions void of calciﬁcations in
Pdgfbret/ret animals show normal distribution of microglia
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Figure 3 Presence of an osteogenic environment around brain calcifications in genetically confirmed PFBC. (A–C)
Immunohistochemistry of bone matrix proteins (in cyan). Brain calcifications in PFBC cases stain for osteocalcin (A), collagen I (B), and
osteopontin (C). (D) Immunohistochemistry for an osteoclast marker. Brain calcifications stain for cathepsin K (in cyan), a protein secreted by
osteoclasts, indicating the presence of osteoclast-like cells. (E) Immunohistochemistry for an osteoblast marker. Cells in the vicinity of brain
calcifications (in cyan) express RUNX2 (in red) localized to the nucleus. Nuclei are visualized using DAPI (in white, A–E). Magnified orthogonal
views of dotted areas show nuclear localization of RUNX2. Scale bars = 30 mm (A–D), 10mm (E), and 3 mm (magnified image, E).
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Figure 4 Neurotoxic astrocytes surround brain calcifications in Pdgfbret/ret animals and behavioral phenotype of Pdgfbret/ret
animals. (A) Podoplanin is expressed by reactive astrocytes surrounding calcifications. GFAP-positive (in white) reactive astrocytes surrounding
brain calcifications (marked with a yellow dotted circle) express podoplanin (in red). (B) marker for neurotoxic astrocytes, C3 (in yellow), co-
localizes with GFAP staining (in cyan) around brain calcifications (in red) in Pdgfbret/ret mouse brains. (C) LCN2 (in white) co-localizes with GFAP
staining (in red). (D) Carboxyethylpyrrole (CEP, in white) is found in GFAP-positive (in red) astrocytes around calcifications in Pdgfbret/ret mouse
brain. Yellow dotted line in A, C and D mark calcifications. Scale bars = 30mm (A), 15mm (B), 10mm (C) and 8mm (D). (E–J) Behavioural
phenotype of Pdgfbret/ret animals. (E) PPI test, where the mean PPI is expressed as a percentage and calculated from the reflex outcome of a
combination of three different prepulses and three different pulses (P = 0.0005); n = 17–20: 17 Pdgfbret/ret, 20 controls. (F) Light-dark box
experiment, where the time spent in the bright area is expressed as a percentage of time during 10 min (P = 0.039); n = 10. (G) Spontaneous
alternation test, where the alternations carried out by the mouse within 5 min are expressed as a percentage (P = 0.0013); n = 18–20: 18
Pdgfbret/ret, 20 controls. (H) Social interaction test, where the time spent with the unfamiliar mouse over the dummy during 5 min is expressed in
percentage (P = 0.241); n = 17–20: 17 Pdgfbret/ret, 20 controls. (I) Open field test, where the total distance travelled by mice during 45 min is
expressed in centimetres (P = 0.0003); n = 18–20: nine Pdgfbret/ret males, nine control males, nine Pdgfbret/ret females, 11 control females (J) Tracking
illustration of the distance one mouse travelled during 45 min. White dotted box marks the centre zone. All data are means  SEM.
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and astrocytes, but as shown previously, calciﬁcations elicit
a strong microglial and astrocyte response (Supplementary
Fig. 3). Astrogliosis is a prominent feature of PFBC path-
ology, but little is known about speciﬁc changes in astro-
cytes. Recent studies show that astrocyte response to injury
is heterogeneous and injury speciﬁc (Pekny and Pekna,
2016). However, the expression of recently described
neurotoxic astrocyte (A1) markers is shared by different
brain diseases (Liddelow et al., 2017). Thus, we tested
whether reactive astrocytes surrounding calciﬁcations ex-
press markers for A1 astrocytes. Figure 4B shows that
GFAP-positive astrocytes surrounding calciﬁcations express
complement 3 (C3), a marker of neurotoxic astrocyte. To
further conﬁrm the neurotoxic response of astrocytes sur-
rounding calciﬁcations, we stained against lipocalin 2
(LCN2), a secreted protein by reactive astrocytes causing
neuronal damage (Bi et al., 2013). Also, LCN2 was
expressed by GFAP-positive astrocytes surrounding
calciﬁcations (Fig. 4C). We also stained for 2-!-carbox-
yethylpyrrole (CEP) adducts since increased phospholipid
oxidation accompanies inﬂammation. Interestingly, we de-
tected CEP immunoreactivity around calciﬁcations, con-
ﬁned to GFAP-positive astrocytes (Fig. 4D). Thus, these
results indicate that astrocytes surrounding calciﬁcations
in addition to a neurotoxic proﬁle show signs of oxidative
damage.
A subset of symptoms exhibited by
PFBC patients is recapitulated in
Pdgfbret/ret animals
Clinical symptoms in PFBC patients are variable and in-
clude cognitive, psychiatric and movement symptoms
(Nicolas et al., 2013b). To assess whether Pdgfbret/ret ani-
mals exhibit a behavioural phenotype, we performed a set
of behavioural tests. We ﬁrst assessed the sensorimotor
gating by measuring the PPI of the acoustic startle reﬂex.
This test measures the reduction in startle response to an
acoustic stimulus (pulse), when the subject is exposed to a
weak acoustic stimulus (prepulse) shortly beforehand
(Supplementary Fig. 4A) (Hoffman and Searle, 1965). We
found a striking main effect for genotype in the PPI, where
Pdgfbret/ret mice presented a drastically decreased PPI
(18%) compared to controls (Fig. 4E). Both, Pdgfbret/ret
and control mice had comparable acoustic startle responses
(Supplementary Fig. 4E) and their startle reﬂex was inten-
siﬁed with an increase in pre-pulse level (Supplementary
Fig. 4F). We then evaluated the impact of genotype on
innate anxiety-like behaviour using the light-dark box
test. The light-dark box test is a widely used test to meas-
ure innate anxiety-like behaviour in rodents and is based
on the natural aversion of mice to brightly illuminated
areas as well as their spontaneous exploratory behaviour
in novel environments (Supplementary Fig. 4B). Pdgfbret/ret
mice displayed a signiﬁcant decrease (8%) in time spent
in the bright area, signifying an increase in innate anxiety-
like behaviour compared to controls (Fig. 4F), which was
not accompanied by changes in locomotor activity.
Working memory was assessed by the spontaneous alter-
ation test, which is based on the novelty preference of mice
and measures the willingness of the tested animals to enter
a new arm of the maze rather than returning to the previ-
ously visited arm (Supplementary Fig. 4C). In the spontan-
eous alternation test, Pdgfbret/ret mice exhibited a robust
reduction in alternation (13%) compared to controls
(Fig. 4G). This observation indicates impaired spatial learn-
ing and memory in Pdgfbret/ret animals. In the social inter-
action test (Supplementary Fig. 4D), Pdgfbret/ret mice spent
more time with the unfamiliar mouse (over 60%) than with
the inanimate object, which was comparable to the behav-
iour of control mice (Fig. 4H). We also observed a signiﬁ-
cant main effect for the cohort in this test (P = 0.0083);
however, this variable did not interact signiﬁcantly with
other dependent variables, i.e. gender or genotype (gen-
der cohort, P = 0.51; genotype cohort, P = 0.23). This
main effect is due to the general reduction in interaction
with objects in the arena, i.e. unfamiliar mouse and dummy
in the second tested cohort. The open ﬁeld exploration test
is a widely used behavioural assay to evaluate locomotor
responses to novel environments in rodents. Pdgfbret/ret
mice showed hyperactivity in the open ﬁeld test (Fig. 4I
and J) where the total distance moved was increased in
Pdgfbret/ret animals. In addition, we observed a signiﬁcant
main effect between genders, where the total distance
moved was increased in male Pdgfbret/ret mice compared
to female Pdgfbret/ret mice (Fig. 4I). Interestingly, male
Pdgfbret/ret mice increased in locomotion over time, unlike
the other groups, where the locomotion decreased over
time (Supplementary Fig. 4G). This overall increase in
locomotion in Pdgfbret/ret animals resulted in an increase
in centre zone entries (Supplementary Fig. 4H), but not
in overall time spent in the centre zone (Supplementary
Fig. 4I). Moreover, we did not observe a preferred spatial
placement (Fig. 4J), suggesting that the movement of the
mice was random and not subject to preference. Altogether,
we found that Pdgfbret/ret animals exhibit sensorimotor
gating deﬁcits, hyperactivity, innate anxiety-like behaviour
and reduced working memory, but unaffected social
interaction.
Discussion
Our study provides a mechanistic insight into the patho-
physiology of PFBC and implicates ossiﬁcation as a cellular
mechanism for the formation of vessel-associated calciﬁca-
tions. We also show that osteogenic environment elicits a
neurotoxic astrocytic response, and that these pathologies
are associated with behavioural changes in Pdgfbret/ret mice,
a mouse model for PFBC. In addition, we demonstrate that
tissue calciﬁcation in Pdgfbret/ret animals is conﬁned to the
CNS and is not caused by systemic alteration.
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Bilateral microvascular calciﬁcation in the brain is a
pathological hallmark of PFBC; however, the pathome-
chanism is not understood. In the current study, we con-
ﬁrm earlier ﬁndings and provide further evidence of the
bone-like consistency of vessel-associated calciﬁcations
using a variety of imaging modalities (i.e. mCT, MRI, ﬂuor-
escent imaging) (Fig. 1, Supplementary Fig. 1 and
Supplementary Video 1). Furthermore, we demonstrate
that these bone-like structures are surrounded by cells ex-
pressing bone cell markers for osteoclasts and osteoblasts
(Fig. 2 and Supplementary Fig. 2). Thus, the calciﬁcation of
capillaries in PFBC is an active process mediated by osteo-
blast-like cells. The formation of bone-like cells often
accompanies soft tissue calciﬁcation. The presence of
these cells has been demonstrated around calciﬁed lesions
in atherosclerosis (Pugliese et al., 2015), and in other gen-
etic diseases of vessel calciﬁcation, such as generalized ar-
terial calciﬁcations of infancy (GACI) (Apschner et al.,
2014), pseudoxanthoma elasticum (PXE) (Hosen et al.,
2014), and in patients with chronic kidney disease
(Nitschke and Rutsch, 2017). In addition, brain vessel cal-
ciﬁcation accompanies also other brain diseases, such as
childhood developmental disorders (e.g. Sturge-Weber syn-
drome) (McCartney and Squier, 2014) and several neuro-
degenerative diseases (e.g. Alzheimer’s disease,
parkinsonism, diffuse neuroﬁbrillary tangles with calciﬁca-
tion), but little is known about the pathomechanism of
vessel calciﬁcation in these diseases. Interestingly, in neuro-
logical disorders, it has been reported that non-collagenous
bone matrix proteins (e.g. osteopontin, osteocalcin) are pre-
sent in capillary-associated calciﬁcations (Fujita et al.,
2003) pointing to similarities in protein content of calciﬁ-
cations with PFBC. Thus, vessel calciﬁcation in PFBC and
other brain diseases could share common pathways with
other ectopic calciﬁcation disorders presenting vessel calci-
ﬁcation, regardless of the initial cause or anatomical loca-
tion. This suggests that therapeutic approaches targeting
vessel calciﬁcation in peripheral tissues could also poten-
tially reduce brain calciﬁcation load in PFBC patients.
A recent study using Slc20a2 heterozygous animals, a
PFBC mouse model, did not ﬁnd evidence of active depos-
ition of mineralized calcium along the vessel wall
(Wallingford et al., 2017). Our data show that an osteo-
genic environment accompanies brain calciﬁcations in
PFBC irrespective of the causative mutation (Fig. 3).
Thus, the lack of evidence of osteoblast-like cells around
brain calciﬁcations in Slc20a2 heterozygous animals
(Wallingford et al., 2017) could be due to variation in
the experimental procedures to detect bone cell markers
around calciﬁcations (e.g. tissue section thickness, tissue
ﬁxation, used antibodies).
In this study we have detected and quantiﬁed brain calci-
ﬁcations in Pdgfbret/ret animals using several ex vivo and
in vivo approaches. We have used immunohistochemical de-
tection on serial brain vibratome sections, bisphosphonate
staining in cleared whole brains (both ex vivo analyses),
and in vivo MRI using phase and SWI post-processing.
Quantiﬁcation of the calciﬁcation load in the brains of
Pdgfbret/ret animals using both in vivo and ex vivo methods
have shown signiﬁcant interindividual variation (Fig. 1). Of
note, the high variation in calciﬁcation load occurs region-
ally. This interindividual variation of calciﬁcation load has
been reported in human PFBC cases, but the clinical signiﬁ-
cance is not clear (Nicolas et al., 2013b). Interindividual
variation in calciﬁcation load was also recently reported in
Slc20a2-deﬁcent animals; however, no quantiﬁcation of cal-
ciﬁcation load was performed (Jensen et al., 2018). This and
our data (Fig. 1) indicate that PFBC mutations are necessary
for the formation of calciﬁcations but the initiation fre-
quency is stochastic. Additional factors other than a gene
mutation contribute to the initiation and/or growth of
vessel-associated calciﬁcations. Thus, mouse models of
PFBC show similarities in disease pathology, such as vari-
ation in calciﬁcation load and the time-dependent growth of
calciﬁcations (Keller et al., 2013; Jensen et al., 2018).
Several CNS pathologies show pathological features in per-
ipheral tissues. For example, patients suffering from cere-
bral autosomal dominant arteriopathy with subcortical
infarcts and leukoencephalopathy (CADASIL), caused by
mutations in the NOTCH3 gene, present with granular
osmiophilic material within smooth muscle cells in brain and
skin blood vessels (Chabriat et al., 2009). A case study on
PFBC individuals carrying PDGFRB and XPR1 mutations
reported microcalciﬁcations in cutaneous vessels (Nicolas
et al., 2017); however, the pathological features were not
identical to those observed in the brain. Nevertheless, we
investigated whether Pdgfbret/ret mice present with calciﬁca-
tions in the peripheral tissues by using mCT imaging. As pre-
viously reported (Keller et al., 2013), we detected calciﬁcations
in the brain (Supplementary Fig. 1C) but not in other tissues.
Further studies that address molecular, hemodynamic and bio-
mechanical differences of vascular beds in various organs
including brain (Jespersen and Ostergaard, 2012; Inden
et al., 2013) may provide clues to why patients with PFBC
develop calciﬁcations in certain brain regions.
In addition, we investigated whether systemic changes
could lead to the development of local vessel calciﬁcation
in the brain by using an in vitro test to measure the calciﬁ-
cation propensity of serum (Pasch et al., 2012). Although
one of the diagnostic criteria for PFBC is the exclusion of
altered serum concentrations of calcium, magnesium and
phosphorus (Nicolas et al., 2013b), the predisposition for
calcium phosphate to precipitate can still be affected by
altered levels of calciﬁcation-inhibiting factors (e.g. fetuin-
A, albumin, magnesium, PPi). Lower levels of serum
fetuin-A, a major systemic inhibitor of calciﬁcation, have
been reported in patients with idiopathic bilateral basal
ganglia calciﬁcations (Demiryurek and Gundogdu, 2018).
Pdgfbret/ret mice, similar to PFBC patients, do not present
with altered calcium, Pi and magnesium levels in the
serum when compared to control mice (Keller et al., 2013)
and results presented in this study show that there is no
difference in serum calciﬁcation propensity between
Pdgfbret/ret and control mice (Supplementary Fig. 1F).
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Taken together, Pdgfbret/ret mice do not show alterations in
the humoral anti-calciﬁcation defence and, thus, the forma-
tion of local vessel calciﬁcation in the brain in Pdgfbret/ret
mice is not triggered by systemic alterations in the serum
calciﬁcation propensity.
It is not yet fully known which cell types are the primar-
ily affected cells in PFBC. Our previous studies have
demonstrated that paracrine PDGF-BB signalling at the
neurovascular unit protects from vessel calciﬁcation
(Keller et al., 2013), further highlighting the importance
of neurovascular unit in disease pathogenesis. PFBC genes
are expressed by different cell types at the neurovascular
unit (i.e. endothelial cells, pericytes, astrocytes, microglia);
however, a recent study demonstrated that MYORG is ex-
pressed only by astrocytes (Yao et al., 2018). Thus, it is
plausible that astrocyte dysfunction is a common denomin-
ator in PFBC pathophysiology. To this end, our study fur-
ther points to the importance of astrocytes in PFBC. First,
we show that astrocytes surrounding calciﬁcations are posi-
tive for CEP adducts (Fig. 4D), which arise exclusively from
the oxidation of docosahexaenoic (DHA)-containing lipids
(Yakubenko and Byzova, 2017). The accumulation of CEP,
a sign of oxidative damage, occurs in many diseases asso-
ciated with chronic inﬂammation (e.g. atherosclerosis,
macular degeneration) but also in autistic brain tissue
(Evans, 2008; Yakubenko and Byzova, 2017). CEP modi-
ﬁcations are strong triggers/catalysts of pathology by indu-
cing pro-inﬂammatory response in macrophages
(Yakubenko and Byzova, 2017). Thus, CEP modiﬁcations
on reactive astrocytes surrounding calciﬁcations in
Pdgfbret/ret mice, in addition of indicating astrocytic oxida-
tive stress around calciﬁcations, might also contribute to
the PFBC pathology by modifying an inﬂammatory re-
sponse in calciﬁcation-associated microglia. Second, we
show that vessel calciﬁcations elicit a speciﬁc astrocytic re-
sponse, which shares similarities with other neurodegenera-
tive diseases. We found that astrocytes surrounding
calciﬁcations are positive for several proteins expressed in
subsets of reactive astrocytes (podoplanin, C3, LCN2)
(Fig. 4A–C). It has been shown that podoplanin is strongly
expressed by a subset of reactive astrocytes in glioblastoma,
and after ischaemic and stab wound injuries (Kolar et al.,
2015). Similarly, we detect a strong podoplanin expression
in Pdgfbret/ret brains only in GFAP-positive astrocytes sur-
rounding calciﬁcations, conﬁrming the presence of a sub-
population of astrocytes possessing a different activation
proﬁle. Additionally, we report that reactive astrocytes
around brain calciﬁcations express C3 (Fig. 4B). Recent
studies have validated C3 as a marker for neurotoxic astro-
cytes (i.e. A1 type) in brain diseases (e.g. Alzheimer’s,
Parkinson’s disease, multiple sclerosis) and in ageing
(Liddelow et al., 2017; Clarke et al., 2018). Reactive astro-
cytes surrounding calciﬁcations express also LCN2
(Fig. 4C), a biomarker for many inﬂammatory diseases,
including atherosclerosis (Oberoi et al., 2015). In the
brain, the astrocyte-derived LCN2 has been shown to be
toxic speciﬁcally for neurons (Bi et al., 2013). Taken
together, these data pinpoint that astrocytes may play an
important role in the pathophysiology of PFBC by poten-
tially leading to neuronal damage and modifying inﬂamma-
tory response.
The clinical manifestations of PFBC are heterogeneous
(Nicolas et al., 2013b). In addition, little is known about
changes in neuronal networks leading to neuropsychiatric
and motor deﬁcits in PFBC. Case studies of few genetic-
ally conﬁrmed PFBC patients presenting with parkinson-
ism point to presynaptic dopaminergic deﬁcit (Paschali
et al., 2009; Koyama et al., 2017). In this study, we
have for the ﬁrst time assessed whether a PFBC mouse
model recapitulates some of the wide-range of neuro-
logical symptoms observed in PFBC patients.
Behavioural testing comprised recognized readouts for
innate anxiety, social interaction, locomotor activity, PPI
and working memory. These tests were selected based on
their relevance to the neurological symptoms observed in
patients with PFBC. In addition, alterations in invariably
calciﬁed brain regions (i.e. basal ganglia) in patients with
PFBC, as well as in animal models of PFBC, could modify
the outcome of these tests. We report that Pdgfbret/ret mice
present with increased anxiety and reduced cognition (Fig.
4F and G), but have no alterations in social interaction
(Fig. 4H). In addition, Pdgfbret/ret mice also present with
deﬁcits in sensorimotor gating demonstrated by reduced
PPI and hyperactivity (Fig. 4E, I and J). This behavioural
phenotype recapitulates a subset of clinical symptoms (e.g.
anxiety, psychosis, altered cognition) observed in PFBC
patients (Nicolas et al., 2013b). It is important to consider
that mouse models of human brain disorders do not re-
capitulate the full spectrum of behavioural symptoms (Del
Pino et al., 2018). However, the behavioural alterations in
Pdgfbret/ret mice are reproducible, which supports the val-
idity of this animal model as an excellent translational
research tool. Currently, it is not clear how capillary cal-
ciﬁcations and/or the neurotoxic astrocytic response in the
thalamus and midbrain in Pdgfbret/ret mice disturb the
neural circuitry leading to these behavioural changes.
However, PPI is executed and modulated by the functional
connection between cortex and nuclei residing in calciﬁca-
tion-prone brain regions (thalamic, midbrain) (Swerdlow
et al., 2001), where vessel calciﬁcations could impair de-
livery of nutrients and oxygen into the neural tissue.
Interestingly, a reduction in PPI and increased locomotion
were reported in mice upon Pdgfrb deletion using Nestin-
Cre (Nakamura et al., 2015). The observed behavioural
phenotype was attributed to the lack of Pdgfrb expression
in neurons (Nguyen et al., 2011). However, it should be
noted that although nestin is a known neural stem cell
marker, it is highly expressed by brain vascular cells,
such as pericytes (Vanlandewijck et al., 2018; Zeisel
et al., 2018), and by reactive astrocytes (Clarke et al.,
1994). Thus, deletion of Pdgfrb using Nestin-Cre could
result in the knock-out of Pdgfrb in cell types other
than neuronal progenitors. Nevertheless, it is intriguing
that the ablation of Pdgfrb leads to similar behavioural
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phenotypes as PDGFB hypomorphism, which further cor-
roborates the conclusion that disturbances in PDGFB/
PDGFRB signalling axis in the CNS lead to an altered
neuronal function.
Taken together, this study provides further insights into the
pathogenesis of cerebrovascular calciﬁcations in PFBC and the
associated changes in neural tissue (Fig. 5).We show that vessel
calciﬁcation is conﬁned to the CNS and is accompanied by an
osteogenic environment in Pdgfbret/retmice. The latter ﬁndings
were validated on autopsy material of genetically conﬁrmed
PFBC cases. We applied different methodologies to visualize
and quantify brain calciﬁcations and demonstrate that there is
a signiﬁcant inter-individual variation in calciﬁcation load. In
addition, we show that vessel calciﬁcation elicits a neurotoxic
astroglial response similar to those described in other neurode-
generative diseases. Ossiﬁcation of the NVU and astrocyte
changes are associated with behavioural alterations in
Pdgfbret/ret mice, exhibiting deﬁcits in the sensorimotor gating
and cognition.
Although future studies using cell-type speciﬁc gene
ablation of PFBC genes are needed to dissect the role
of different cell types in PFBC aetiology, our study
points to astrocytes as important players in the patho-
physiology of PFBC. Future studies will be directed to-
wards identiﬁcation of pharmacologically targetable
pathways that reverse vessel ossiﬁcation and/or neuro-
toxic astrocytic response, and whether this leads to a
reversal of behavioural phenotypes observed in
Pdgfbret/ret mice.
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Figure 5 Alterations at the neurovascular unit accompanying vessel calcification in a mouse model of PFBC. Homeostasis:
PDGFB/PDGFRB signalling at the neurovascular unit prevents vessel calcification. PDGFB is secreted by the endothelium and PDGFRB is
expressed by mural cells and low level by astrocytes. Ossification of the neurovascular unit (NVU) in animal model of PFBC: altered PDGFB/
PDGFRB signalling leads to the formation of bone cells (i.e. cells expressing osteoclast, osteoblast, osteocyte markers) and the deposition of
structural bone proteins (e.g. collagen I, osteopontin, osteocalcin). Bone-like structures are closely surrounded by activated microglia and
activated astrocytes. Astrocytes surrounding calcifications show signs of oxidative stress (i.e. CEP-positivity) and express markers for a subset of
reactive astrocytes (LCN2, podoplanin), including the one for neurotoxic astrocytes (C3). Ossified vessels and neurotoxic astrocytic response is
associated with neuronal dysfunction presenting in reduced PPI, hyperactivity, increased anxiety and impaired cognition. A = astrocyte;
AEF = astrocyte endfeet; BM = basement membrane; E = endothelium; M = microglia; P = pericyte. Figure is modified from Betsholtz and Keller
(2014).
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